Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Roy S. Herbst, MD, PhD, on pemextrexed maintenance treatment

Dr. Herbst, Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, on whether to continue pemetrexed maintenance after successful treatment of the patient with carboplatin / pemetrexed / pembrolizumab

Published: 08 June 2018

Recent Videos

video

Will Tomorrow's CAR-T Therapy Innovations Solve Today's Challenges?

Sharon Karlsberg, Principal, Oncology, ZS Associates, considers the future of CAR-T therapies with Michael R. Bishop, MD, Professor of Medicine, ...

video

How Can Manufacturers Help Institutions Prepare for CAR-T Therapies?

Sharon Karlsberg, Principal, Oncology, ZS Associates, considers how manufacturers can help institutions prepare for CAR-T therapies with Michael R. Bishop, ...

video

How Can a CAR-T Center Get Established and Effectively Treat Patients?

Sharon Karlsberg, Principal, Oncology, ZS Associates, discusses how a CAR-T center becomes established and effectively treats patients with Michael R. ...

video

Sai-Hong Ignatius Ou, MD, PhD, comments on Tumor Mutation Burden (TMB) as a biomarker in NSCLC

Dr. Ou considers whether Tumor Mutation Burden (TMB) is a valid biomarker in determining non-small cell lung cancer (NSCLC) patients ...

video

Sai-Hong Ignatius Ou, MD, PhD, on pemetrexed maintenance therapy

Dr. Ou provides opinion on whether he would continue pemetrexed maintenance after successful treatment of a patient with carboplatin, pemetrexed, ...

video

Sai-Hong Ignatius Ou, MD, PhD, discusses key takeaways from the IMpower150 study at ASCO 2018

Dr. Ou elaborates on the key takeaways from the IMpower150 study in non-small cell lung cancer (NSCLC) and whether the ...

video

Sai-Hong Ignatius Ou, MD, PhD, comments on combo chemotherapy & immunotherapy in 2nd line NSCLC

Dr. Ou offers opinion on how chemotherapy should be combined with immunotherapy in the treatment of 2nd line non-small cell ...

video

Sai-Hong Ignatius Ou, MD, PhD, regarding combo chemotherapy & immunotherapy in 1st line NSCLC

Dr. Ou discusses outcomes from Keynote 189, specifically, how chemotherapy should be combined with immunotherapy in the treatment of 1st ...

video

Sai-Hong Ignatius Ou, MD, PhD, on testing for PD-L1 expression in NSCLC

Dr. Ou offers opinion on whether every non-small cell lung cancer (NSCLC) patient should be tested for PD-L1 expression and ...

video

Benjamin Philip Levy, MD, on Tumor Mutation Burden (TMB) as a biomarker in NSCLC

Dr. Levy elaborates on whether Tumor Mutation Burden (TMB) is a valid biomarker to determine those non-small cell lung cancer ...

Related Videos

video-image

How Can a CAR-T Center Get Established and Effectively Treat Patients?

video-image

How Can Manufacturers Help Institutions Prepare for CAR-T Therapies?

video-image

Will Tomorrow's CAR-T Therapy Innovations Solve Today's Challenges?

video-image

Sai-Hong Ignatius Ou, MD, PhD, comments on combo chemotherapy & immunotherapy in 2nd line NSCLC

video-image

Sai-Hong Ignatius Ou, MD, PhD, discusses key takeaways from the IMpower150 study at ASCO 2018

video-image

Benjamin Philip Levy, MD, offers opinion on testing for PD-L1 expression in NSCLC

video-image

Sai-Hong Ignatius Ou, MD, PhD, on pemetrexed maintenance therapy

video-image

Benjamin Philip Levy, MD, discusses the practice-changing outcomes from Keynote 189

video-image

Sai-Hong Ignatius Ou, MD, PhD, comments on Tumor Mutation Burden (TMB) as a biomarker in NSCLC

video-image

Benjamin Philip Levy, MD, regarding combo chemotherapy & immunotherapy in 2nd line NSCLC

video-image

Benjamin Philip Levy, MD, on options for NSCLC patients who progress on 1st line I-O & chemotherapy

video-image

Benjamin Philip Levy, MD, comments on the IMpower150 clinical trial in NSCLC

video-image

Benjamin Philip Levy, MD, on maintenance therapy following carboplatin, pemetrexed & pembrolizumab

video-image

Benjamin Philip Levy, MD, on Tumor Mutation Burden (TMB) as a biomarker in NSCLC

video-image

Sai-Hong Ignatius Ou, MD, PhD, on testing for PD-L1 expression in NSCLC

video-image

Sai-Hong Ignatius Ou, MD, PhD, regarding combo chemotherapy & immunotherapy in 1st line NSCLC

video-image

Howard (Jack) West, MD, regarding PDL-1 expression and NSCLC

video-image

Novel Endpoints: Working Through Today's Challenges to Improve the Future of Cancer Care

video-image

Howard (Jack) West, MD, regarding the combination of immunotherapy & chemotherapy in NSCLC

video-image

Howard (Jack) West, MD, on treatment options for patients who progress on I-O & chemotherapy